AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01798745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
Study NCT01798745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Solution.
Description: Aqueous Solution, 10mg/mL.
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Granule Capsule (A)
Description: GSK2190915A granule filled in to Gelatin capsules
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Semi-solid Lipid Capsule (B)
Description: GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Liquid Lipid Capsule (C)
Description: GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Milled Tablet
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Study NCT02224521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 Micronised Tablet
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Study NCT01396044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic checklist
Description: Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
Study NCT01396044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal prompting
Description: Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
Study NCT02429700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02429700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT02429700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
Study NCT03947216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active drug: pimavanserin 17mg (2 strength tablets)
Description: Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
Study NCT02429700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
Study NCT02429700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
Study NCT03967132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Ready to feed infant formula, feed ad libitum
Study NCT03967132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Ready to feed infant formula, feed ad libitum
Study NCT03967132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference Group
Description: Human milk, breast feeding ad libitum
Study NCT00826397 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
Study NCT03900169 — intervention group
Intervention type: GENETIC
Intervention: Genetic
Description: Lipid profile
Study NCT03417557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfilcon A lens (test)
Description: contact lens
Study NCT03417557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon B lens (control)
Description: contact lens
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Virginia Tobacco 5% nicotine strength
Description: JUUL ENDS - Virginia Tobacco 5% nicotine strength
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Virginia Tobacco 3% nicotine strength
Description: JUUL ENDS - Virginia Tobacco 3% nicotine strength
Study NCT04149587 — intervention group
Intervention type: DRUG
Intervention: Brodalumab
Description: Brodalumab will be administered per dose and schedule specified in the arm.
Study NCT03953209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 50Mg Tablet
Description: Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Menthol 5% nicotine strength
Description: JUUL ENDS - Menthol 5% nicotine strength
Study NCT02010723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
Study NCT02010723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sclerotherapy with aethoxysclerol foam
Description: foam sclerotherapy with aethoxysclerol foam
Study NCT02042911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
Study NCT01666886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Study NCT02639208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PatientsLikeMe (PLM)
Study NCT00673790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol with concomitant losartan or lisinopril
Description: Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
Study NCT00673790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ with concomitant losartan or lisinopril
Description: Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
Study NCT00673790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with concomitant losartan or lisinopril
Description: Placebo with concomitant treatment consisting of lisinopril 10 mg total daily dosage, oral administration or losartan 50 mg total daily dosage, oral administration.
Study NCT04244747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: induction of labor by breast stimulation
Study NCT04244747 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: induction of labor by catheter balloon
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Menthol 3% nicotine strength
Description: JUUL ENDS - Menthol 3% nicotine strength
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mint 5% nicotine strength
Description: JUUL ENDS - Mint 5% nicotine strength
Study NCT03366285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Attachment story completion taks (ASCT)
Description: Bonding quality
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mint 3% nicotine strength
Description: JUUL ENDS - Mint 3% nicotine strength
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mango 5% nicotine strength
Description: JUUL ENDS - Mango 5% nicotine strength
Study NCT03953209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100Mg Tablet
Description: Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
Study NCT03953209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 200Mg
Description: Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
Study NCT04088175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL ENDS - Mango 3% nicotine strength
Description: JUUL ENDS - Mango 3% nicotine strength
Study NCT01387100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Rehabilitation Intervention
Description: Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
Study NCT02976740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
Study NCT02976740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunological Agent
Description: Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
Study NCT02976740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunological Factors
Description: Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
Study NCT04989062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Controlled attenuation parameter and liver stiffness measurement are measured.
Study NCT04989062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical impedance analysis
Description: Body composition measures including fat mass, fat-free mass, percentage body fat in total body and body segments are obtained.
Study NCT04989062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine unclear magnetic resonance metabolomics
Description: Metabolites in the urine are estimated by 600 MHz nuclear magnetic resonance.
Study NCT04989062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hand grip strength
Description: Hand grip strength in both hands is measured by hand-held dynamometer.
Study NCT00892697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if \< 75 kg).
Study NCT03947216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 2 tablets containing same excipients except active compound
Description: Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of severity of ICD (impulse control disorders)
Description: Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors
Description: Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP, ISI, PDSS-2) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT00892697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if \< 75 kg).
Study NCT00892697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if \< 75 kg).
Study NCT02168647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Lifestyle counseling
Description: Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
Study NCT02168647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of quality of life
Description: Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of depression
Description: Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of cognition
Description: Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
Study NCT03947216 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of severity of Parkinson Disease
Description: Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
Study NCT03947216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
Study NCT03947216 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood analysis
Description: Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
Study NCT03947216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac monitoring
Description: Electrocardiogram will be realized at day 0, 28 and 56.
Study NCT03947216 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac monitoring
Description: Electrocardiogram will be realized at day 0, 28 and 56.
Study NCT03064568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 100Mcg Tab
Study NCT03064568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04219670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Wearable sensors
Description: Utilizing wireless wearable sensors, to capture quantitative biometric and movement-based data.
Study NCT03855449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eDECIDE Web-based Intervention Group
Description: Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention
Study NCT03855449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eDECIDE Web-based Intervention Group
Description: Will conduct 18 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.~After the completion of the task analysis participants will be recruited for the eDECIDE web-based intervention
Study NCT03817424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB7734
Description: Participants will receive VIB7734 via injection.
Study NCT03817424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to VIB7734 via injection.
Study NCT04310995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil 5mg tid
Description: oral Nicorandil Tablets 5mg (5mg per tablet) three times daily for 24 weeks
Study NCT04310995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem 180mg qd
Description: oral Diltiazem Sustained-release Tables180mg (90 mg per tablet) once daily for 24 weeks
Study NCT04310995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate 50mg qd
Description: oral Isosorbide Mononitrate Sustained-release Capsules 50 mg (50mg per capsule) once daily for 24 weeks
Study NCT04064489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TRIPscore
Description: TRIPcast score calculation
Study NCT01446081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.